Market Overview

UPDATE: Jefferies Raises PT to $41 on Bristol-Myers Squibb on Long-Term Growth Prospects

Related BMY
Fast Money Picks For September 29 - Yahoo! Inc., Exxon Mobil Corporation And More
Bristol-Myers Squibb Co In Patent Suit Vs. Merck & Co., Inc. Over Skin Cancer Drug
The Stocks Already in Correction Mode (Fox Business)

Jefferies maintained Bristol-Myers Squibb (NYSE: BMY) with a Buy rating and raisd the price target from $39.00 to $41.00.

Jefferies said, "2013 will likely deliver several major catalysts that will shape the direction of Bristol-Myers' mid to long term growth. We believe that Eliquis will beat launch expectations providing meaningful earnings momentum, whilst several major R&D catalysts (anti-PD1 and Yervoy) further expand the PE multiple. We reiterate our Buy rating and have increased our PT to $41 (from $39)."

Bristol-Myers Squibb closed at $36.93 on Monday.

Latest Ratings for BMY

DateFirmActionFromTo
Aug 2014Deutsche BankInitiates Coverage onHold
Aug 2014JefferiesMaintainsHold
Jul 2014JefferiesMaintainsHold

View More Analyst Ratings for BMY
View the Latest Analyst Ratings

Posted-In: JefferiesAnalyst Color Price Target Analyst Ratings

 

Related Articles (BMY)

Around the Web, We're Loving...

Partner Network

Get Benzinga's Newsletters